A recent study has found that nearly one in six children and adolescents prescribed GLP-1 receptor agonists—medications like Ozempic and Wegovy—developed nutritional deficiencies within a year of starting treatment. The research adds to growing concerns about the side effects of these drugs in young people, who are increasingly being prescribed them for weight management.
The study, published in a peer-reviewed journal, tracked pediatric patients and identified deficiencies in key nutrients such as iron, vitamin B12, and vitamin D. While GLP-1 drugs are effective for weight loss and diabetes control, they can suppress appetite and reduce food intake, potentially leading to inadequate nutrient absorption. Experts note that these deficiencies can have long-term health consequences if left unaddressed.
Doctors emphasize the importance of monitoring nutritional status in young patients on GLP-1 medications. They recommend regular blood tests and, when necessary, dietary counseling or supplements to prevent deficiencies. The findings highlight the need for balanced approaches to pediatric obesity treatment that include nutritional support alongside medication.
As the use of GLP-1s in children continues to rise, further research is needed to understand the full scope of risks and benefits. Parents and healthcare providers should weigh these potential nutritional risks against the medications' proven benefits for weight and metabolic health.
